NFC
FOLD

Northeast Financial Consultants’s Amicus Therapeutics FOLD Stock Holding History

Northeast Financial Consultants’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-13,495
Closed -$203K – 302
2020
Q2 		$203K Buy
+13,495
New +$164K 0.02% 268

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Northeast Financial Consultants's FOLD Position: Q3 2020 in Review

Northeast Financial Consultants sold out of Amicus Therapeutics (FOLD) in Q3 2020, closing a stake of 13,495 shares — an estimated $203K sold.

Northeast Financial Consultants first reported a position in FOLD in Q2 2020 and held it in 1 quarter. The position peaked at $203K in Q2 2020. 251 funds tracked by Wall St. Rank hold FOLD as of Q3 2020.

  • Northeast Financial Consultants reported no remaining Amicus Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Northeast Financial Consultants sold 13,495 Amicus Therapeutics shares in Q3 2020, an estimated $203K.
  • Northeast Financial Consultants first reported a position in Amicus Therapeutics in Q2 2020 and held it in 1 quarter.
  • Northeast Financial Consultants's Amicus Therapeutics position peaked at $203K in Q2 2020.
  • 251 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2020.

Based on Northeast Financial Consultants's 13F filing for Q3 2020, filed 29 Oct 2020.